News

February 22, 2023 Download PDF EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 clinical trials for Fabry disease cardiomyopathy. All three…

BOSTON–(BUSINESS WIRE)–Feb. 16, 2023– Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar with nine months of follow up evaluating two key clinical endpoints: tumor control and…

February 16, 2023 Download PDF EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced that the Company will host a live webcast on February 22 to present interim clinical data from its 4D-310 INGLAXA Phase…

– sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC) – Submission based on MARCH Phase 3 study with high statistical significance (p<0.0001) between LIVMARLI versus placebo, and 62% of itch severity scores reported as mild to none – If approved, LIVMARLI…

FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,000 shares of common stock and 2,500 restricted stock units (“RSUs”) to one new employee under Mirum’s 2020 Inducement Plan. The Compensation…

February 9, 2023 PDF Version BOSTON–(BUSINESS WIRE)–Feb. 9, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: Live webcasts of the SVB fireside chat and…